Development and Validation of Stability-Indicating RP-HPLC Methods for The Quantitative Analysis of Novel Pharmaceutical Drugs

Abstract

ABSTRACT The analytical characterization of novel active pharmaceutical ingredients (APIs) requires rigorous, robust, and validated methodologies to ensure chemical integrity, therapeutic efficacy, and safety across the product shelf life. Stability-indicating Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) has emerged as the definitive gold-standard analytical technique for isolating, identifying, and quantifying target active drug molecules in the co-presence of their degradants, process-related impurities, synthetic intermediates, and excipient matrices. This comprehensive review delivers an in-depth, systematic investigation into the architectural principles, development strategies, and validation protocols governing stability-indicating RP-HPLC methods in strict alignment with International Council for Harmonisation (ICH) Q2(R1), Q2(R2), and Q1A(R2) regulatory guidelines. We critically examine the stress-testing paradigms—encompassing acid and base hydrolysis, oxidative degradation, thermal stress, photolysis, and humidity exposure—required to elucidate intrinsic degradation pathways and verify chromatographic mass balance. The review details the integration of Analytical Quality by Design (AQbD) and Design of Experiments (DoE) workflows, focusing on Method Operable Design Regions (MODR) to optimize stationary phase chemistries, mobile phase composition, pH buffers, gradient profiles, and photodiode array (PDA/DAD) peak purity evaluations. Furthermore, quantitative validation parameters—including specificity, linearity, limit of detection (LOD), limit of quantification (LOQ), precision, accuracy, and robustness—are thoroughly evaluated alongside hyphenated spectroscopic techniques (HPLC-MS/MS, HPLC-NMR) for degradation degradant characterization. Critical analytical bottlenecks such as co-eluting isomeric degradants, column bleeding, ion pairing instabilities, and stationary phase dewetting are addressed, followed by future perspectives on Ultra-High-Performance Liquid Chromatography (UHPLC), green analytical chemistry (GAC), supercritical fluid chromatography (SFC), and artificial intelligence-driven automated chromatographic retention modeling.

KEYWORDS: Stability-Indicating Method (SIM); RP-HPLC; Stress Degradation; ICH Q2(R2) Guidelines; Analytical Quality by Design (AQbD); Forced Degradation; Peak Purity; Pharmaceutical Validation.